08:41 AM EDT, 09/16/2025 (MT Newswires) -- Coya Therapeutics ( COYA ) said Tuesday that early preclinical data from the first animal cohort testing its investigational therapy, COYA 303, demonstrated broad systemic and central immunomodulatory effects in a mouse model of neuroinflammation.

The company said the treatment significantly reduced lipopolysaccharide-induced pro-inflammatory immune cells and cytokines, increased anti-inflammatory immune subsets, and lowered brain inflammation compared to untreated controls.

Coya said the results support the potential of COYA 303 to target inflammatory pathways involved in Alzheimer's disease and other neurodegenerative conditions.

Two additional experimental cohorts are underway to assess how timing of treatment initiation affects outcomes, the company said, adding it plans to present the full data in a peer-reviewed setting once available.